⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL600731 | 1.00 | — | — | |
| SCHEMBL602183 | 1.00 | — | — | |
| SCHEMBL8589543 | 0.81 | — | — | |
| SCHEMBL31064500 | 0.79 | GRIK1 (0.35) | — | |
| SCHEMBL600192 | 0.77 | GGT1 (0.50) | — | |
| SCHEMBL600191 | 0.77 | GGT1 (0.50) | — | |
| SCHEMBL602005 | 0.77 | GGT1 (0.50) | — | |
| SCHEMBL15083315 | 0.76 | — | — | |
| SCHEMBL3047206 | 0.75 | — | — | |
| SCHEMBL9747384 | 0.75 | TSHR (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 188 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2564863-B1 | Triazole linked macrocyclic peptides | AILERON THERAPEUTICS INC (US) | 2017-08-23 | — | — | EP | claimed |
| US-8637686-B2 | Triazole macrocycle systems | AILERON THERAPEUTICS, INC. (US) | 2014-01-28 | — | — | US | claimed |
| EP-2564863-A2 | Triazole linked macrocyclic peptides | Aileron Therapeutics, Inc. (US) | 2013-03-06 | — | — | EP | claimed |
| EP-2114428-B1 | Triazole linked macrocyclic peptides | AILERON THERAPEUTICS INC (US) | 2012-10-31 | — | — | EP | claimed |
| US-20110263815-A1 | TRIAZOLE MACROCYCLE SYSTEMS | AILERON THERAPEUTICS, INC., A DELAWARE CORPORATION (US) | 2011-10-27 | — | — | US | claimed |
| US-7981999-B2 | Peptidomimetics; kits; macrocyclization | AILERON THERAPEUTICS, INC. (US) | 2011-07-19 | — | — | US | claimed |
| EP-2114428-A2 | TRIAZOLE MACROCYCLE SYSTEMS | Aileron Therapeutics, Inc. (US) | 2009-11-11 | — | — | EP | claimed |
| US-20080262200-A1 | Triazole Macrocycle Systems | AILERON THERAPEUTICS, INC., A DELAWARE CORPORATION (US) | 2008-10-23 | — | — | US | claimed |
| WO-2008104000-A2 | TRIAZOLE MACROCYCLE SYSTEMS | AILERON THERAPEUTICS, INC. (US) | 2008-08-28 | — | — | WO | claimed |
| US-12492225-B2 | Melanocyte-regulating peptides | IDP DISCOVERY PHARMA, S.L. (ES) | 2025-12-09 | — | — | US | disclosed |
| US-20240083943-A1 | VEGF-REGULATING PEPTIDES | IDP DISCOVERY PHARMA, S.L. (ES) | 2024-03-14 | — | — | US | disclosed |
| EP-4271480-A1 | VEGF-REGULATING PEPTIDES | IDP Discovery Pharma, S.L. (ES) | 2023-11-08 | — | — | EP | disclosed |
| CN-116964074-A | Peptides that modulate VEGF | IDP研发制药有限公司 | 2023-10-27 | — | — | CN | disclosed |
| CN-111263768-B | anticancer peptides | IDP研发制药有限公司 | 2023-10-13 | — | — | CN | disclosed |
| EP-2114428-A2 | TRIAZOLE MACROCYCLE SYSTEMS | Aileron Therapeutics, Inc. (US) | 2009-11-11 | — | — | EP | disclosed |
| US-20090275519-A1 | Therapeutic peptidomimetic macrocycles | AILERON THERAPEUTICS, INC. (US) | 2009-11-05 | — | — | US | disclosed |
| WO-2009126292-A2 | BIOLOGICALLY ACTIVE PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. (US) | 2009-10-15 | — | — | WO | disclosed |
| WO-2009099677-A2 | THERAPEUTIC PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. (US) | 2009-08-13 | — | — | WO | disclosed |
| US-20080262200-A1 | Triazole Macrocycle Systems | AILERON THERAPEUTICS, INC., A DELAWARE CORPORATION (US) | 2008-10-23 | — | — | US | disclosed |
| WO-2008104000-A2 | TRIAZOLE MACROCYCLE SYSTEMS | AILERON THERAPEUTICS, INC. (US) | 2008-08-28 | — | — | WO | disclosed |